ENGN
Engene Holdings Inc
NASDAQ · Biotechnology
$9.55
+0.69 (+7.79%)
Open$8.95
Previous Close$8.86
Day High$9.78
Day Low$8.95
52W High$12.25
52W Low$2.65
Volume—
Avg Volume399.1K
Market Cap639.70M
P/E Ratio—
EPS$-2.29
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+584.1% upside
Current
$9.55
$9.55
Target
$65.33
$65.33
$48.23
$65.33 avg
$96.03
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 102.93M | 108.44M | 88.87M |
| Net Income | -18,276,199 | -22,730,064 | -15,420,094 |
| Profit Margin | -17.8% | -21.0% | -17.4% |
| EBITDA | -27,166,221 | -28,388,210 | -21,820,067 |
| Free Cash Flow | -19,844,248 | -21,752,544 | -13,746,863 |
| Rev Growth | +6.4% | +6.6% | +8.6% |
| Debt/Equity | 0.41 | 0.31 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |